scholarly journals Hematopoietic Cell Transplantation as Curative Therapy for Idiopathic Myelofibrosis, Advanced Polycythemia Vera, and Essential Thrombocythemia

2007 ◽  
Vol 13 (3) ◽  
pp. 355-365 ◽  
Author(s):  
Daniella M.B. Kerbauy ◽  
Theodore A. Gooley ◽  
George E. Sale ◽  
Mary E.D. Flowers ◽  
Kristine C. Doney ◽  
...  
Keyword(s):  
Polycythemia Vera ◽  
Cell Transplantation ◽  
Essential Thrombocythemia ◽  
Hematopoietic Cell Transplantation ◽  
Hematopoietic Cell ◽  
Idiopathic Myelofibrosis ◽  
Curative Therapy

scholarly journals A Systematic Review of Machine Learning Techniques in Hematopoietic Stem Cell Transplantation (HSCT)

Sensors ◽  
2020 ◽  
Vol 20 (21) ◽  
pp. 6100
Author(s):  
Vibhuti Gupta ◽  
Thomas M. Braun ◽  
Mosharaf Chowdhury ◽  
Muneesh Tewari ◽  
Sung Won Choi
Keyword(s):  
Machine Learning ◽  
Systematic Review ◽  
Cell Transplantation ◽  
Hematopoietic Cell Transplantation ◽  
Hematopoietic Cell ◽  
Machine Learning Techniques ◽  
Support Vector ◽  
Hematopoietic Stem ◽  
Curative Therapy ◽  
Learning Techniques

Machine learning techniques are widely used nowadays in the healthcare domain for the diagnosis, prognosis, and treatment of diseases. These techniques have applications in the field of hematopoietic cell transplantation (HCT), which is a potentially curative therapy for hematological malignancies. Herein, a systematic review of the application of machine learning (ML) techniques in the HCT setting was conducted. We examined the type of data streams included, specific ML techniques used, and type of clinical outcomes measured. A systematic review of English articles using PubMed, Scopus, Web of Science, and IEEE Xplore databases was performed. Search terms included “hematopoietic cell transplantation (HCT),” “autologous HCT,” “allogeneic HCT,” “machine learning,” and “artificial intelligence.” Only full-text studies reported between January 2015 and July 2020 were included. Data were extracted by two authors using predefined data fields. Following PRISMA guidelines, a total of 242 studies were identified, of which 27 studies met the inclusion criteria. These studies were sub-categorized into three broad topics and the type of ML techniques used included ensemble learning (63%), regression (44%), Bayesian learning (30%), and support vector machine (30%). The majority of studies examined models to predict HCT outcomes (e.g., survival, relapse, graft-versus-host disease). Clinical and genetic data were the most commonly used predictors in the modeling process. Overall, this review provided a systematic review of ML techniques applied in the context of HCT. The evidence is not sufficiently robust to determine the optimal ML technique to use in the HCT setting and/or what minimal data variables are required.

Salvage Allogeneic Hematopoietic Cell Transplantation with Fludarabine and Total Body Irradiation (3 or 4 Gy) after Failure of First Allografts.

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 3272-3272
Author(s):  
Boglarka Gyurkocza ◽  
Thai M. Cao ◽  
Rainer F. Storb ◽  
Thoralf Lange ◽  
Wendy Leisenring ◽  
...  
Keyword(s):  
Cell Transplantation ◽  
Umbilical Cord ◽  
Total Body Irradiation ◽  
Hematopoietic Cell Transplantation ◽  
Chronic Gvhd ◽  
Hematopoietic Cell ◽  
Allogeneic Hematopoietic Cell Transplantation ◽  
Unrelated Donor ◽  
Idiopathic Myelofibrosis ◽  
Total Body

Abstract We analyzed data from 38 patients (median age = 56, range: 8 – 68 years) with acute leukemia (n=15), chronic idiopathic myelofibrosis (n=6), myelodysplastic syndrome with or without myeloproliferative disorder (n=5), chronic myeloid leukemia (n=4), non- Hodgkin lymphoma (n=4), aplastic anemia (n=2), multiple myeloma (n=1) and renal cell carcinoma (n=1), who underwent salvage allogeneic hematopoietic cell transplantation (HCT) for allograft failure. In 14 cases the original donors were used for second HCT, while in 24 cases different donors were identified (Table 1). Conditioning regimens for first HCTs included total body irradiation (TBI; 2 Gy) with or without fludarabine (Flu; n=28), myeloablative regimens (busulfan-cyclophosphamide, n=6; cyclophosphamide-TBI, n=2); and other, cyclophosphamide-anti-thymocyte globulin-based regimens (n=3). Conditioning for salvage HCT consisted of Flu 30 mg/m2/day on days -4 to -2 followed by TBI of 3 (n=24) or 4 (n=14) Gy on day 0. Cyclosporine and mycophenolate mofetil were used for postgrafting immunosuppression. The median time between first and salvage HCTs was 91 (range, 29 to 1004) days. Sustained second grafts were achieved in 34 patients (89%), while grafts failed in 4 patients (11%), all of whom had idiopathic myelofibrosis. With a median follow-up among surviving patients of 2.0 (range, 0.3 to 7.8) years, the 2 and 4 year Kaplan-Meier survival estimates were 49% (95% CI: 31%, 66%) and 42% (95% CI: 23%, 61%), respectively. The 2 year relapse-rate and non-relapse mortality were 36% (95% CI: 20%, 52%) and 25% (95% CI: 11%, 41%), respectively. The cumulative incidences of grades 2–4 acute and moderate-severe chronic graft-versus-host disease (GVHD) at 2 years were 42% and 41%, respectively. Four patients with chronic GVHD discontinued systemic immunosuppressive therapy at a median of 2.5 years. Within the limitations of the small patient numbers studied, TBI dose (3 vs. 4 Gy), same vs. different donors for salvage HCT, donor type (related, unrelated, HLA-haploidentical related vs. double umbilical cord), and HCT comorbidity scores did not appear to affect outcomes. Based on this retrospective multicenter analysis, we conclude that graft failure following allogeneic HCT can be effectively overcome by second transplantation using conditioning with Flu and low dose TBI (3 or 4 Gy), which should be further investigated in a prospective manner. Table 1. Donors in 1st and 2nd HCTs. HLA-MURD: HLA-matched unrelated donor; HLA-MMURD: HLA-mismatched unrelated donor, UCB: umbilical cord blood. 2nd HCT Different Donor 1st HCT Same Donor HLA-MURD HLA-MMURD Double UCB HLA-haploidentical HLA-identical sibling 11 11 - - - - HLA-MURD 17 3 10 4 - - HLA-MMURD 8 - 1 7 - - Double UCB 2 - - - 1 1

Curative Therapy of Advanced Essential Thrombocythemia or Polycythemia Vera by Hemopoietic Stem Cell Transplantation

2002 ◽  
Vol 43 (7) ◽  
pp. 1409-1414 ◽  
Author(s):  
Uwe Platzbecker ◽  
Ted Gooley ◽  
Claudio Anasetti ◽  
Frederick R. Appelbaum ◽  
Bruce Clurman ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Polycythemia Vera ◽  
Cell Transplantation ◽  
Essential Thrombocythemia ◽  
Hemopoietic Stem Cell ◽  
Curative Therapy ◽  
Hemopoietic Stem Cell Transplantation

scholarly journals Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups

2015 ◽  
Vol 21 (11) ◽  
pp. 1883-1887 ◽  
Author(s):  
H. Joachim Deeg ◽  
Christopher Bredeson ◽  
Stephanie Farnia ◽  
Karen Ballen ◽  
Vikas Gupta ◽  
...  
Keyword(s):  
Cell Transplantation ◽  
Hematopoietic Cell Transplantation ◽  
Age Groups ◽  
Hematopoietic Cell ◽  
Curative Therapy

scholarly journals Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors

Blood ◽  
2012 ◽  
Vol 120 (7) ◽  
pp. 1367-1379 ◽  
Author(s):  
Vikas Gupta ◽  
Parameswaran Hari ◽  
Ronald Hoffman
Keyword(s):  
Cell Transplantation ◽  
Hematopoietic Cell Transplantation ◽  
Treatment Strategies ◽  
Significant Risk ◽  
Clinical Situation ◽  
Hematopoietic Cell ◽  
Inhibitor Therapy ◽  
Allogeneic Hematopoietic Cell Transplantation ◽  
Curative Therapy ◽  
Modern Drug

Abstract The discovery of JAK2617F mutation paved the way for the development of small molecule inhibitors of JAK1/2 resulting in first approved JAK1/2 inhibitor, ruxolitinib, for the treatment of patients with myelofibrosis (MF). Although JAK1/2 inhibitor therapy is effective in decreasing the burden of symptoms associated with splenomegaly and MF-related constitutional symptoms, it is neither curative nor effective in reducing the risk of leukemic transformation. Presently, allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for MF. A significant risk of regimen-related toxicities, graft failure, and GVHD are major barriers to the success of HCT in MF. Because of significant HCT-associated morbidity and mortality, divergent opinions regarding its appropriate role in this clinical situation have emerged. In this review, the risk-benefit ratios of modern drug therapy compared with HCT in MF patients are analyzed. A risk-adapted approach individualized to each patient's biologic characteristics and comorbidities is described, which is currently warranted in determining optimal treatment strategies for patients with MF. Inclusion of JAK1/2 inhibitor therapy in future transplant conditioning regimens may provide an opportunity to overcome some of these barriers, resulting in greater success with HCT for MF patients.

Sign in / Sign up

Export Citation Format

Share Document